Welcome to our dedicated page for DEVONIAN HEALTH GROUP news (Ticker: DVHGF), a resource for investors and traders seeking the latest updates and insights on DEVONIAN HEALTH GROUP stock.
Devonian Health Group Inc. (TSXV: GSD, OTCQB: DVHGF) is a clinical stage pharmaceutical and biopharmaceutical company that regularly issues news related to its development of prescription drugs for auto-immune inflammatory and fibroinflammatory diseases. As a medicinal and botanical manufacturing company with a focus on prescription botanical drug products, its updates often center on scientific progress, clinical programs and corporate developments.
News coverage for Devonian frequently highlights advances with its lead candidate Thykamine™, the first pharmaceutical product from its SUPREX™ platform. Releases have described comparative in vitro studies against widely used anti-inflammatory drugs, in vivo work in models of MASH and fibrosis, and Phase II clinical data in ulcerative colitis and atopic dermatitis. The company also reports on patent filings, new potential indications and formulation work, such as development of oral forms for gastrointestinal diseases.
Investors and observers can also expect regular financial and corporate news. Devonian publishes quarterly and annual financial results, including commentary on distribution revenues generated by its Altius commercialization subsidiary and on how those revenues support Thykamine™ development. Other announcements cover private placements, stock option grants, changes in officers and directors, shareholder meeting results, option and rights plans, and matters related to financial reporting and exchange approvals.
Because Devonian operates at the intersection of clinical-stage drug development and pharmaceutical distribution in Canada, its news flow combines R&D milestones, regulatory and intellectual property updates, and capital markets activity. Following the DVHGF news stream can help readers track the evolution of its botanical-based pipeline, the status of distribution agreements managed through Altius, and key corporate decisions that shape the company’s long-term strategy.
Devonian Health Group Inc. announced the acceptance for publication of positive Phase 2 trial results for Thykamine™ in treating mild-to-moderate Atopic Dermatitis in the Journal of Drugs in Dermatology. Conducted in 162 patients, the trial demonstrated significant efficacy, particularly with the 0.10% cream formulation, which showed statistical significance across primary and secondary endpoints. This publication highlights the potential of Thykamine™ as an effective botanical treatment amidst rising global demand for Atopic Dermatitis therapies, predicted to surpass $21.8 billion by 2027.
Devonian Health Group Inc. (TSXV: GSD; OTCQB: DVHGF) announced shareholder approval for a new Restricted Share Unit Plan (RSU Plan) at its annual meeting on February 25, 2022. The plan allows granting of restricted share units to various corporate personnel, capped at 10% of outstanding shares, approximately 10,908,701 shares. This RSU Plan is pending approval from the TSX Venture Exchange. Devonian focuses on developing botanical pharmaceutical products for treating autoimmune diseases, with its flagship product, Thykamine, ready for phase 3 clinical development.
Devonian Health Group Inc. has commenced quoting its shares on the OTCQB under the symbol DVHGF, while continuing its listing on the TSXv as GSD. This move enhances access to a broader range of U.S. investors and potentially improves liquidity and trading experience. The OTCQB is a reputable platform for early-stage companies, ensuring transparency and adherence to high financial standards. Additionally, eligibility for DTC facilitates easier trading and settlement, further supporting Devonian's strategic growth in the botanical pharmaceutical sector.